Aptose Biosciences, Inc. (APTO): Price and Financial Metrics


Aptose Biosciences, Inc. (APTO)

Today's Latest Price: $4.24 USD

0.00 (0.00%)

Updated Jan 28 11:13am

Add APTO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

APTO Stock Price Chart Interactive Chart >

Price chart for APTO

APTO Price/Volume Stats

Current price $4.24 52-week high $9.25
Prev. close $4.24 52-week low $3.92
Day low $4.20 Volume 297,186
Day high $4.31 Avg. volume 920,513
50-day MA $4.87 Dividend yield N/A
200-day MA $5.82 Market Cap 376.86M

Aptose Biosciences, Inc. (APTO) Company Bio


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company was founded in 1986 and is based in Mississauga, Canada.


APTO Latest News Stream


Event/Time News Detail
Loading, please wait...

APTO Latest Social Stream


Loading social stream, please wait...

View Full APTO Social Stream

Latest APTO News From Around the Web

Below are the latest news stories about Aptose Biosciences Inc that investors may wish to consider to help them evaluate APTO as an investment opportunity.

Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs

Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

Yahoo | January 6, 2021

Is APTO A Good Stock To Buy Now According To Hedge Funds?

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

Yahoo | December 19, 2020

Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use

Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.

Yahoo | December 16, 2020

Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

Yahoo | December 16, 2020

Roche (RHHBY) Gets FDA Nod for Shorter Infusion Time of Ocrevus

The FDA approves Roche's (RHHBY) Ocrevus for two-hour infusion time, dosed twice-yearly to patients with relapsing or primary progressive MS.

Yahoo | December 15, 2020

Read More 'APTO' Stories Here

APTO Price Returns

1-mo 3.16%
3-mo -5.57%
6-mo -16.21%
1-year -34.16%
3-year 34.60%
5-year 44.22%
YTD -3.20%
2020 -22.75%
2019 196.86%
2018 -14.73%
2017 61.15%
2016 -45.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7485 seconds.